Search the Newsreel

[10-Q] NEUROCRINE BIOSCIENCES INC Quarterly Earnings Report

Neurocrine Biosciences Inc. (NBIX) filed its quarterly earnings report (Form 10-Q) with the SEC, detailing its financial performance for the quarter ended June 30, 2026. Key highlights include the completion of the Soleno Therapeutics Inc. acquisition, adding VYKAT XR to its commercial portfolio, and …

Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results

Total Second-Quarter 2026 Revenue Grew 39% Year-Over-Year to $959 Million INGREZZA® (valbenazine) 2026 Net Sales Guidance Raised to $2.825 to $2.875 Billion Acquisition of Soleno Therapeutics Completed in May 2026 SAN DIEGO, July 30, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced …

Neurocrine Biosciences Inc (NBIX) (Q2 2026) Earnings Call Highlights: Record Revenue and Raised ...

This article first appeared on GuruFocus. Total Revenue: Over $950 million in Q2 2026, representing nearly 40% year-over-year growth. Non-GAAP EPS: $2.85 per share for the second quarter. INGREZZA Net Sales: $716 million in Q2, up 15% year-over-year, driven by record new patient additions. …

Vertex Just Paid $10 Billion for Crinetics. Here's Why Viking Therapeutics Could Be the Next Big Pharma Takeover Target

This has been an active year in the mergers-and-acquisitions landscape across the biopharmaceutical industry. One of the more notable deals was Vertex Pharmaceuticals' acquisition of Crinetics Pharmaceuticals for $10 billion in cash (the transaction hasn't closed yet). This is the largest acquisition in Vertex …

Form 4 Neurocrine Biosciences Inc For: 30 July By Investing.com

This article reports on a Form 4 filing for Neurocrine Biosciences Inc, specifically for activity on July 30th. It prominently displays the company's stock symbol NBIX and its recent percentage change in value. The content primarily consists of section headers and navigation links, with …

Neurocrine Biosciences Releases Q2 2026 Financial Results

Neurocrine Biosciences reported strong Q2 2026 financial results, with non-GAAP earnings per share of $2.85, significantly beating analyst expectations, and revenue reaching $959.0M, an 8.0% increase over forecasts. The company's flagship product, INGREZZA, contributed $716.0M to revenue, and full-year revenue guidance was set between …

Neurocrine (NBIX) Reports Q2 Earnings: What Key Metrics Have to Say

Neurocrine Biosciences (NBIX) reported $959 million in revenue for the quarter ended June 2026, representing a year-over-year increase of 39.5%. EPS of $2.85 for the same period compares to $1.06 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $901.54 …

Neurocrine Biosciences (NBIX) Surpasses Q2 Earnings and Revenue Estimates

Neurocrine Biosciences (NBIX) came out with quarterly earnings of $2.85 per share, beating the Zacks Consensus Estimate of $2.26 per share. This compares to earnings of $1.06 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an …

Neurocrine Biosciences Q2 revenue rises 39% to $959 million

Earnings Flash (NBIX) Neurocrine Biosciences, Inc. Posts Q2 Adjusted EPS $2.85 per Share, vs. FactSet Est of $1.66

Neurocrine Biosciences Inc. (NBIX) reported Q2 adjusted earnings per share of $2.85, significantly surpassing the FactSet estimate of $1.66. The company also announced Q2 revenue of $959.0 million, exceeding the FactSet estimate of $891.2 million. The article highlights recent news related to Neurocrine Biosciences, …

Neurocrine (NBIX) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates

Wall Street analysts expect Neurocrine Biosciences (NBIX) to post quarterly earnings of $2.26 per share in its upcoming report, which indicates a year-over-year increase of 113.2%. Revenues are expected to be $901.54 million, up 31.1% from the year-ago quarter. The consensus EPS estimate for …

Crinetics Pharmaceuticals Number of Employees 2026 | Employee Count & Headcount Data

Crinetics Pharmaceuticals (CRNX) has approximately 611 employees worldwide as of March 2026, marking a 114.5% growth from 285 employees in 2023. The company, headquartered in San Diego, California, is actively hiring with 163 job postings in 2026. Its workforce is primarily concentrated in the …

Crinetics Pharmaceuticals Inc (CRNX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Crinetics Pharmaceuticals Inc (CRNX), detailing its current price momentum score, support and resistance levels, and various technical indicators. It outlines buy, neutral, and sell signals based on MACD, RSI, KDJ, and moving averages, concluding with a "Neutral" …

Biotech Stocks At 52-Week Highs - ANIK & CHE Rise With Q2 Results, ICUI, NBIX, RPRX

Several biotech stocks, including Anika Therapeutics (ANIK), Chemed Corporation (CHE), ICU Medical (ICUI), Neurocrine Biosciences (NBIX), and Royalty Pharma (RPRX), reached new 52-week highs on July 29, 2026. This surge was primarily driven by strong second-quarter financial results and ongoing positive clinical research updates …

Crinetics Pharmaceuticals Inc (CRNX) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Crinetics Pharmaceuticals Inc (CRNX), noting its current valuation score of 8.48, which ranks it 124th in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -16.33, comparing it to recent highs and lows. …

Crinetics Pharmaceuticals Inc (CRNX) Financial Health: Profitability & Balance Sheet Analysis

Crinetics Pharmaceuticals Inc (CRNX) has a current financial score of 7.15, ranking it 143 out of 384 in the Biotechnology & Medical Research industry, indicating stable financial status but low operating efficiency. The company recently reported a quarterly revenue of $10.73 million, marking a …

Neurocrine Biosciences Inc (NBIX) Financial Health: Profitability & Balance Sheet Analysis

Neurocrine Biosciences Inc (NBIX) currently holds a financial score of 8.50, placing it 50th out of 155 companies in the Pharmaceuticals industry, indicating stable financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 42.25% to $814.50 million and …

Neurocrine Biosciences, Inc. Revenue Breakdown – BX:NB3

Neurocrine Biosciences, Inc. (BX:NB3) reported a total revenue of 2.27 billion CHF last year, primarily driven by its Pharmaceuticals segment. The majority of this revenue, also 2.27 billion CHF, came from operations within the United States. This indicates a strong reliance on the pharmaceutical …

Neurocrine Biosciences stock hits all-time high at 181.3 USD

Neurocrine Biosciences Inc. (NBIX) reached an all-time stock high of $181.30, reflecting a 34.56% increase over the past year. Analysts have revised earnings estimates upward, and the stock trades at a PEG ratio of 0.22, suggesting it remains undervalued according to InvestingPro analysis despite …

CRNX|Crinetics Pharmaceuticals Inc|Price:83.890|Chg%:+0.030

This article provides a comprehensive stock analysis of Crinetics Pharmaceuticals Inc (CRNX), highlighting its strong fundamentals, high growth potential, and current valuation. TradingKey's stock score places CRNX at 6th out of 384 in the Biotechnology & Medical Research industry. The company is performing strongly …

Neurocrine’s 33% quarter outruns weak drugmaker breadth, but average volume keeps the move under review

NBIX closed at $175.8, just 3.0% below its 52-week high, with an active weekly Trend Signal and positive Market Dynamics. The reservation is participation, with latest volume at only 1.0x the 13-week average.

Crinetics Pharmaceuticals Inc (CRNX) Cash Flow

This article provides a detailed cash flow statement for Crinetics Pharmaceuticals Inc (CRNX), including operating, investing, and financing cash flows presented in both quarterly and annual formats. It highlights key financial figures such as operating cash flow of -377.92M in fiscal 2025 and capital …

Net margin % of Neurocrine Biosciences, Inc. – HAM:NB3

This page from TradingView provides financial information for Neurocrine Biosciences, Inc. (HAM:NB3), specifically focusing on its net margin percentage. It details market performance on the Hamburg Stock Exchange and offers tools for financial analysis. The content primarily lists product offerings and company information related …

Neurocrine Gears Up to Report Q2 Earnings: What's in the Cards?

Neurocrine Biosciences (NBIX) is slated to report its second-quarter 2026 earnings on July 30, with investors keenly focused on the sales performance of its key products, Ingrezza and Crenessity, and updates on its neuroscience pipeline. The Zacks Consensus Estimate projects revenues of $901.54 million …

JPMorgan discloses 6.3% Neurocrine stake in 13G/A filing (NBIX)

JPMorgan Chase & Co. has filed an amended Schedule 13G/A, reporting a beneficial ownership of 6.3% in Neurocrine Biosciences, Inc. common stock, totaling 6,338,240 shares. The filing details JPMorgan's sole voting power over 5,719,691 shares and sole dispositive power over 6,337,388 shares. This disclosure …

Weekly Recap: Guggenheim hikes NBIX price target and Siddhanti named CBO

Guggenheim has reiterated a Buy rating on Neurocrine Biosciences (NBIX) and increased its price target to $200. Additionally, Neurocrine Biosciences has appointed Samir Siddhanti as its new Chief Business Officer, tasked with driving growth, business development, and corporate strategy, aiming to maximize the value …

Crinetics Pharmaceuticals Inc (CRNX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on Crinetics Pharmaceuticals Inc. (CRNX) stock, focusing on its dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years. The page also presents current stock pricing and market capitalization information.

Crinetics Pharmaceuticals Inc (CRNX) Income Statement

This article provides the quarterly and annual income statements for Crinetics Pharmaceuticals Inc (CRNX), detailing financial performance from FY2017Q1 to FY2026Q1. It includes metrics such as total revenue, operating expenses, R&D expenses, operating profit, net non-operating interest income/expenses, income before and after tax, and …

Crinetics Pharmaceuticals Inc (CRNX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Crinetics Pharmaceuticals Inc (CRNX), listing its major shareholders and their proportions. It also presents institutional holding trends over recent quarters, and identifies related ETFs that include CRNX. Top shareholders include Fidelity Management & Research Company LLC and …

Neurocrine Biosciences (NBIX) Refreshes Leadership On A Narrative That Still Sees Undervaluation

Neurocrine Biosciences (NBIX) has appointed new leadership, including a Chief Business Officer and three Senior Vice Presidents, amidst a rising stock price with a 90-day return of 37.28% and a one-year return of 33.02%. The company is considered undervalued with a fair value of …

Crinetics Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:CRNX

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) generated $7.70 million USD in revenue last year, primarily from its Novel Therapeutics segment. The United States was the company's largest contributing region, accounting for the entire $7.70 million USD. This represents a significant increase from the previous year's …

How Investors Are Reacting To Neurocrine Biosciences (NBIX) Leadership Hires In Business And Market Access

Neurocrine Biosciences recently appointed Samir Siddhanti as Chief Business Officer and several Senior VPs, aiming to strengthen commercial execution and broaden its biopharma portfolio. While these hires are seen as positive for the company's long-term strategy, particularly in business development and market access for …

Neurocrine Biosciences Inc (NBIX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Neurocrine Biosciences Inc (NBIX), identifying its major institutional holders and their respective proportions. It also outlines the types of shareholders, the historical institutional shareholding, and recent shareholder activities. Additionally, it lists several ETFs that include NBIX in …

Neurocrine Hires Market Access Chief, Promotes Two Executives

Neurocrine Biosciences has appointed three new Senior Vice Presidents to strengthen its leadership team, focusing on expanding its commercial portfolio and advancing its neuroscience pipeline. Bret Paulson joins as SVP, Market Access, while David Bradfute is promoted to SVP and Global Head of Intellectual …

Neurocrine Biosciences names three senior vice presidents By Investing.com

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has appointed three new senior vice presidents to its leadership team: Bret Paulson as Senior Vice President of Market Access, David Bradfute as Senior Vice President and Global Head of Intellectual Property, and Aaron Vosburgh as Senior Vice President of …

Neurocrine Biosciences Announces Key Leadership Hiring, Promotions

SAN DIEGO, July 23, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of three Senior Vice Presidents, further strengthening its leadership team as the company executes its next phase of growth, expands its commercial portfolio and advances one of the …